speb/financial-data huggingface dataset:
TCBIO balance_sheet (annual, 2025-12-31) — Capital Stock: 300518000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 300518000.00
TCBIO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 2099118000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 2099118000.00
TCBIO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Federal Funds Sold: 2099118000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Federal Funds Sold: 2099118000.00
TCBIO cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -17250000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -4312000.00
TCBIO balance_sheet (annual, 2025-12-31) — Cash Financial: 201315000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Cash Financial: 201315000.00
TCBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 404269000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -1132364000.00
TCBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -1854113000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 36163000.00
TCBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 360154000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 130494000.00
TCBIO cash_flow (annual, 2025-12-31) — Change In Account Payable: -68921000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -2638000.00
TCBIO cash_flow (annual, 2025-12-31) — Change In Payable: -68921000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Change In Payable: -2638000.00
TCBIO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -68921000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -2638000.00
TCBIO cash_flow (annual, 2025-12-31) — Change In Receivables: -57773000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Change In Receivables: -17824000.00
TCBIO cash_flow (annual, 2025-12-31) — Change In Working Capital: -126694000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -20462000.00
TCBIO cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -57773000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -17824000.00
TCBIO cash_flow (annual, 2025-12-31) — Changes In Cash: -1089690000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Changes In Cash: -965707000.00
TCBIO balance_sheet (annual, 2025-12-31) — Common Stock: 518000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Common Stock: 518000.00
TCBIO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 3331382000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 3331382000.00
TCBIO cash_flow (annual, 2025-12-31) — Common Stock Payments: -185850000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -126616000.00
TCBIO balance_sheet (annual, 2025-12-31) — Current Debt: 300000000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Current Debt: 300000000.00
TCBIO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 300000000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 300000000.00
TCBIO cash_flow (annual, 2025-12-31) — Deferred Income Tax: 15887000.00
TCBIO cash_flow (annual, 2025-12-31) — Deferred Tax: 15887000.00
TCBIO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 52166000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 15875000.00
TCBIO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 52166000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 15875000.00
TCBIO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 312994000.00
TCBIO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 96347000.00
TCBIO cash_flow (annual, 2025-12-31) — End Cash Position: 2099118000.00
TCBIO cash_flow (quarterly, 2025-12-31) — End Cash Position: 2099118000.00
TCBIO cash_flow (annual, 2025-12-31) — Financing Cash Flow: 404269000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -1132364000.00
TCBIO cash_flow (annual, 2025-12-31) — Free Cash Flow: 347585000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 130835000.00
TCBIO cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -5094000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: -610000.00
TCBIO income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -1886000.00
TCBIO income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 0.00
TCBIO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -64585000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -64585000.00
TCBIO income_statement (annual, 2025-12-31) — General And Administrative Expense: 498413000.00
TCBIO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 111127000.00
TCBIO balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (annual, 2025-12-31) — Gross PPE: 131688000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Gross PPE: 131688000.00
TCBIO balance_sheet (annual, 2025-12-31) — Held To Maturity Securities: 725722000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Held To Maturity Securities: 725722000.00
TCBIO cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 70178000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 2776000.00
TCBIO income_statement (annual, 2025-12-31) — Insurance And Claims: 17911000.00
TCBIO income_statement (quarterly, 2025-12-31) — Insurance And Claims: 2276000.00
TCBIO income_statement (annual, 2025-12-31) — Interest Expense: 743148000.00
TCBIO income_statement (quarterly, 2025-12-31) — Interest Expense: 176877000.00
TCBIO income_statement (annual, 2025-12-31) — Interest Income: 1771785000.00
TCBIO income_statement (quarterly, 2025-12-31) — Interest Income: 444314000.00
TCBIO cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 760112000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 179521000.00
TCBIO balance_sheet (annual, 2025-12-31) — Invested Capital: 4251957000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Invested Capital: 4251957000.00
TCBIO cash_flow (annual, 2025-12-31) — Investing Cash Flow: -1854113000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 36163000.00
TCBIO balance_sheet (annual, 2025-12-31) — Investments And Advances: 4723099000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 4723099000.00
TCBIO balance_sheet (annual, 2025-12-31) — Long Term Debt: 620575000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 620575000.00
TCBIO balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 620575000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 620575000.00
TCBIO cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -40435000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 0.00
TCBIO balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 50213000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 50213000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -185850000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -126616000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 312994000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 96347000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 100659000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 330244000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Net Interest Income: 1028637000.00
TCBIO income_statement (quarterly, 2025-12-31) — Net Interest Income: 267437000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -199818000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -100751000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -595435000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 55000000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -40435000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 0.00
TCBIO balance_sheet (annual, 2025-12-31) — Net PPE: 88003000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Net PPE: 88003000.00
TCBIO cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -12569000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 341000.00
TCBIO cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: -555000000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Net Short Term Debt Issuance: 55000000.00
TCBIO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 3629886000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 3629886000.00
TCBIO income_statement (annual, 2025-12-31) — Normalized Income: 330244000.00
TCBIO income_statement (quarterly, 2025-12-31) — Normalized Income: 100659000.00
TCBIO income_statement (annual, 2025-12-31) — Occupancy And Equipment: 47619000.00
TCBIO income_statement (quarterly, 2025-12-31) — Occupancy And Equipment: 12803000.00
TCBIO cash_flow (annual, 2025-12-31) — Operating Cash Flow: 360154000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 130494000.00
TCBIO cash_flow (annual, 2025-12-31) — Operating Gains Losses: -3208000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -610000.00
TCBIO income_statement (annual, 2025-12-31) — Operating Revenue: 1255779000.00
TCBIO income_statement (quarterly, 2025-12-31) — Operating Revenue: 327483000.00
TCBIO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 44253688.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 44253688.00
TCBIO balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 300000000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 300000000.00
TCBIO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -64585000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -64585000.00
TCBIO income_statement (annual, 2025-12-31) — Other Non Interest Expense: 154476000.00
TCBIO income_statement (quarterly, 2025-12-31) — Other Non Interest Expense: 43284000.00
TCBIO balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 0.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 0.00
TCBIO balance_sheet (annual, 2025-12-31) — Payables: 6716000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Payables: 6716000.00
TCBIO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 6716000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 6716000.00
TCBIO balance_sheet (annual, 2025-12-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (annual, 2025-12-31) — Preferred Stock: 300000000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 300000000.00
TCBIO cash_flow (annual, 2025-12-31) — Preferred Stock Dividend Paid: -17250000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Preferred Stock Dividend Paid: -4312000.00
TCBIO income_statement (annual, 2025-12-31) — Preferred Stock Dividends: 17250000.00
TCBIO income_statement (quarterly, 2025-12-31) — Preferred Stock Dividends: 4312000.00
TCBIO balance_sheet (annual, 2025-12-31) — Preferred Stock Equity: 300000000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (annual, 2025-12-31) — Pretax Income: 432710000.00
TCBIO income_statement (quarterly, 2025-12-31) — Pretax Income: 132285000.00
TCBIO cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: -7364000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 195000.00
TCBIO income_statement (annual, 2025-12-31) — Professional Expense And Contract Services Expense: 50112000.00
TCBIO income_statement (quarterly, 2025-12-31) — Professional Expense And Contract Services Expense: 11580000.00
TCBIO balance_sheet (annual, 2025-12-31) — Properties: 81475000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Properties: 81475000.00
TCBIO cash_flow (annual, 2025-12-31) — Purchase Of Investment: -1136644000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -293454000.00
TCBIO cash_flow (annual, 2025-12-31) — Purchase Of PPE: -12569000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: 341000.00
TCBIO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 52166000.00
TCBIO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 15875000.00
TCBIO cash_flow (annual, 2025-12-31) — Repayment Of Debt: -40435000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: 0.00
TCBIO cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -185850000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -126616000.00
TCBIO balance_sheet (annual, 2025-12-31) — Retained Earnings: 2808645000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 2808645000.00
TCBIO income_statement (annual, 2025-12-31) — Salaries And Wages: 480502000.00
TCBIO income_statement (quarterly, 2025-12-31) — Salaries And Wages: 108851000.00
TCBIO cash_flow (annual, 2025-12-31) — Sale Of Investment: 936826000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 192703000.00
TCBIO income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 17449000.00
TCBIO income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 5404000.00
TCBIO income_statement (annual, 2025-12-31) — Selling General And Administration: 515862000.00
TCBIO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 116531000.00
TCBIO balance_sheet (annual, 2025-12-31) — Share Issued: 51786456.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Share Issued: 51786456.00
TCBIO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 36759000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 8145000.00
TCBIO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 3631382000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 3631382000.00
TCBIO balance_sheet (annual, 2025-12-31) — Tangible Book Value: 3329886000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 3329886000.00
TCBIO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (annual, 2025-12-31) — Tax Provision: 102466000.00
TCBIO income_statement (quarterly, 2025-12-31) — Tax Provision: 31626000.00
TCBIO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.24
TCBIO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.24
TCBIO balance_sheet (annual, 2025-12-31) — Total Assets: 31540274000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Total Assets: 31540274000.00
TCBIO balance_sheet (annual, 2025-12-31) — Total Capitalization: 4251957000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 4251957000.00
TCBIO balance_sheet (annual, 2025-12-31) — Total Debt: 920575000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Total Debt: 920575000.00
TCBIO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 3631382000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 3631382000.00
TCBIO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 27908892000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 27908892000.00
TCBIO balance_sheet (annual, 2025-12-31) — Trading Securities: 3924000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Trading Securities: 3924000.00
TCBIO balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 7532768.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 7532768.00
TCBIO balance_sheet (annual, 2025-12-31) — Treasury Stock: 487692000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 487692000.00
TCBIO income_statement (quarterly, 2026-03-31) — +Total Revenue: 323985000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 9420000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1077139000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 3955879000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 2099118000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -1357000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 300520000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 2956611000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Federal Funds Sold: 2956611000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -4313000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Cash Financial: 254428000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 1911981000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -1142017000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 87529000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -43059000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Change In Payable: -43059000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -43059000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Change In Receivables: 16089000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -26970000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 16089000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Changes In Cash: 857493000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Common Stock: 520000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 3306207000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -75141000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Current Debt: 0.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 0.00
TCBIO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 12816000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 12816000.00
TCBIO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 69475000.00
TCBIO cash_flow (quarterly, 2026-03-31) — End Cash Position: 2956611000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 1911981000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 86172000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: -5604000.00
TCBIO income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: 0.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -86739000.00
TCBIO income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 144224000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Held To Maturity Securities: 709594000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 1620000.00
TCBIO income_statement (quarterly, 2026-03-31) — Insurance And Claims: 4877000.00
TCBIO income_statement (quarterly, 2026-03-31) — Interest Expense: 164375000.00
TCBIO income_statement (quarterly, 2026-03-31) — Interest Income: 419094000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 180511000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 4184500000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -1142017000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 4673355000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 397599000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 878293000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 878293000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 397599000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -134525000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -75141000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 69475000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 73788000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Net Interest Income: 254719000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 37491000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -66926000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 263074000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Net PPE: 85698000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -1357000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Net Short Term Debt Issuance: -330000000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 3604711000.00
TCBIO income_statement (quarterly, 2026-03-31) — Normalized Income: 73788000.00
TCBIO income_statement (quarterly, 2026-03-31) — Occupancy And Equipment: 12405000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 87529000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -5604000.00
TCBIO income_statement (quarterly, 2026-03-31) — Operating Revenue: 323985000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 43671305.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 0.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -86739000.00
TCBIO income_statement (quarterly, 2026-03-31) — Other Non Interest Expense: 39987000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 0.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Payables: 9420000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 9420000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 300000000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Preferred Stock Dividend Paid: -4313000.00
TCBIO income_statement (quarterly, 2026-03-31) — Preferred Stock Dividends: 4313000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (quarterly, 2026-03-31) — Pretax Income: 94417000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: -9560000.00
TCBIO income_statement (quarterly, 2026-03-31) — Professional Expense And Contract Services Expense: 11980000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -134520000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -1357000.00
TCBIO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 12816000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -134525000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -75141000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 2878120000.00
TCBIO income_statement (quarterly, 2026-03-31) — Salaries And Wages: 139347000.00
TCBIO cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 172011000.00
TCBIO income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 4972000.00
TCBIO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 149196000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Share Issued: 51974496.00
TCBIO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 17499000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 3606207000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 3304711000.00
TCBIO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (quarterly, 2026-03-31) — Tax Provision: 20629000.00
TCBIO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.22
TCBIO balance_sheet (quarterly, 2026-03-31) — Total Assets: 33486484000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 4484500000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Total Debt: 878293000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 3606207000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 29880277000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Trading Securities: 7882000.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 8303191.00
TCBIO balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 562833000.00
TCBK balance_sheet (annual, 2021-12-31) — Current Debt: 50087000.00
TCBK balance_sheet (annual, 2021-12-31) — Current Debt And Capital Lease Obligation: 50087000.00
TCBK cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: 0.00
TCBK balance_sheet (annual, 2021-12-31) — Other Current Borrowings: 50087000.00
TCBK income_statement (annual, 2021-12-31) — Other Gand A: 20743000.00
TCBK income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: 1523000.00
TCBK cash_flow (annual, 2021-12-31) — Sale Of PPE: 2743000.00
TCBK income_statement (annual, 2022-12-31) — +Total Revenue: 402519000.00
TCBK balance_sheet (annual, 2022-12-31) — Accounts Payable: 1167000.00
TCBK balance_sheet (annual, 2022-12-31) — Accounts Receivable: 31856000.00
TCBK balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -61657000.00
TCBK income_statement (annual, 2022-12-31) — Amortization: 6334000.00
TCBK cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 6334000.00
TCBK cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 6334000.00
TCBK income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 6334000.00
TCBK balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 2598000.00
TCBK income_statement (annual, 2022-12-31) — Basic Average Shares: 33331513.00
TCBK income_statement (annual, 2022-12-31) — Basic EPS: 3.85
TCBK cash_flow (annual, 2022-12-31) — Beginning Cash Position: 768421000.00
TCBK balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 64018000.00
TCBK cash_flow (annual, 2022-12-31) — Capital Expenditure: -3623000.00
TCBK balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 29004000.00
TCBK balance_sheet (annual, 2022-12-31) — Capital Stock: 697448000.00
TCBK balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 107230000.00
TCBK balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Federal Funds Sold: 124480000.00
TCBK cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -35797000.00
TCBK balance_sheet (annual, 2022-12-31) — Cash Financial: 96323000.00
TCBK cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -100862000.00
TCBK cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -723224000.00
TCBK cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 162895000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Account Payable: -287000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 17087000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Payable: -287000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -287000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Receivables: -9170000.00
TCBK cash_flow (annual, 2022-12-31) — Change In Working Capital: 7630000.00
TCBK cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -9170000.00
TCBK cash_flow (annual, 2022-12-31) — Changes In Cash: -661191000.00
TCBK balance_sheet (annual, 2022-12-31) — Common Stock: 697448000.00
TCBK cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -35797000.00
TCBK balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1046416000.00
TCBK cash_flow (annual, 2022-12-31) — Common Stock Payments: -27148000.00
TCBK balance_sheet (annual, 2022-12-31) — Construction In Progress: 1217000.00
TCBK balance_sheet (annual, 2022-12-31) — Current Debt: 47905000.00
TCBK balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 47905000.00
TCBK cash_flow (annual, 2022-12-31) — Deferred Income Tax: -8022000.00
TCBK cash_flow (annual, 2022-12-31) — Deferred Tax: -8022000.00
TCBK cash_flow (annual, 2022-12-31) — Depreciation: 12045000.00
TCBK cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 18379000.00
TCBK income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 6334000.00
TCBK cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 18379000.00
TCBK income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 6334000.00
TCBK income_statement (annual, 2022-12-31) — Diluted Average Shares: 33331513.00
TCBK income_statement (annual, 2022-12-31) — Diluted EPS: 3.83
TCBK income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 125419000.00
TCBK cash_flow (annual, 2022-12-31) — End Cash Position: 107230000.00
TCBK cash_flow (annual, 2022-12-31) — Financing Cash Flow: -100862000.00
TCBK cash_flow (annual, 2022-12-31) — Free Cash Flow: 159272000.00
TCBK cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: 340000.00
TCBK cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -1070000.00
TCBK income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -340000.00
TCBK balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -193905000.00
TCBK income_statement (annual, 2022-12-31) — General And Administrative Expense: 132994000.00
TCBK balance_sheet (annual, 2022-12-31) — Goodwill: 304442000.00
TCBK balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 321112000.00
TCBK balance_sheet (annual, 2022-12-31) — Gross PPE: 160846000.00
TCBK balance_sheet (annual, 2022-12-31) — Held To Maturity Securities: 160983000.00
TCBK cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 41000000.00
TCBK income_statement (annual, 2022-12-31) — Insurance And Claims: 3142000.00
TCBK income_statement (annual, 2022-12-31) — Interest Expense: 9529000.00
TCBK income_statement (annual, 2022-12-31) — Interest Income: 354368000.00
TCBK cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 9290000.00
TCBK balance_sheet (annual, 2022-12-31) — Invested Capital: 1412061000.00
TCBK cash_flow (annual, 2022-12-31) — Investing Cash Flow: -723224000.00
TCBK balance_sheet (annual, 2022-12-31) — Investments And Advances: 2616019000.00
TCBK balance_sheet (annual, 2022-12-31) — Land And Improvements: 25899000.00
TCBK balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 29004000.00
TCBK balance_sheet (annual, 2022-12-31) — Long Term Debt: 365645000.00
TCBK balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 394649000.00
TCBK balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 42850000.00
TCBK cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 426883000.00
TCBK cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -27148000.00
TCBK balance_sheet (annual, 2022-12-31) — Net Debt: 258415000.00
TCBK income_statement (annual, 2022-12-31) — Net Income: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 125419000.00
TCBK cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 125419000.00
TCBK income_statement (annual, 2022-12-31) — Net Interest Income: 344839000.00
TCBK cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -392806000.00
TCBK cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 214518000.00
TCBK cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: 214518000.00
TCBK cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 1514000.00
TCBK balance_sheet (annual, 2022-12-31) — Net PPE: 99189000.00
TCBK cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 3067000.00
TCBK balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 725304000.00
TCBK income_statement (annual, 2022-12-31) — Normalized Income: 127967735.00
TCBK income_statement (annual, 2022-12-31) — Occupancy And Equipment: 21226000.00
TCBK cash_flow (annual, 2022-12-31) — Operating Cash Flow: 162895000.00
TCBK cash_flow (annual, 2022-12-31) — Operating Gains Losses: -3388000.00
TCBK income_statement (annual, 2022-12-31) — Operating Revenue: 402519000.00
TCBK balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 33331513.00
TCBK balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 47905000.00
TCBK balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -193905000.00
TCBK balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 16670000.00
TCBK cash_flow (annual, 2022-12-31) — Other Non Cash Items: -6103000.00
TCBK income_statement (annual, 2022-12-31) — Other Non Interest Expense: 36319000.00
TCBK balance_sheet (annual, 2022-12-31) — Other Properties: 26862000.00
TCBK balance_sheet (annual, 2022-12-31) — Other Receivables: 7726000.00
TCBK balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 2452438000.00
TCBK income_statement (annual, 2022-12-31) — Other Special Charges: -1070000.00
TCBK balance_sheet (annual, 2022-12-31) — Payables: 1167000.00
TCBK balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 1167000.00
TCBK balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
TCBK income_statement (annual, 2022-12-31) — Pretax Income: 173907000.00
TCBK cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 1190000.00
TCBK income_statement (annual, 2022-12-31) — Professional Expense And Contract Services Expense: 4392000.00
TCBK cash_flow (annual, 2022-12-31) — Purchase Of Investment: -699035000.00
TCBK cash_flow (annual, 2022-12-31) — Purchase Of PPE: -3623000.00
TCBK balance_sheet (annual, 2022-12-31) — Receivables: 39582000.00
TCBK income_statement (annual, 2022-12-31) — Reconciled Depreciation: 18379000.00
TCBK cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -27148000.00
TCBK income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 6253000.00
TCBK balance_sheet (annual, 2022-12-31) — Retained Earnings: 542873000.00
TCBK income_statement (annual, 2022-12-31) — Salaries And Wages: 129852000.00
TCBK cash_flow (annual, 2022-12-31) — Sale Of Investment: 306229000.00
TCBK cash_flow (annual, 2022-12-31) — Sale Of PPE: 6690000.00
TCBK income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 3694000.00
TCBK income_statement (annual, 2022-12-31) — Selling General And Administration: 136688000.00
TCBK balance_sheet (annual, 2022-12-31) — Share Issued: 33331513.00
TCBK income_statement (annual, 2022-12-31) — Special Income Charges: -5183000.00
TCBK cash_flow (annual, 2022-12-31) — Stock Based Compensation: 3869000.00
TCBK balance_sheet (annual, 2022-12-31) — Stockholders Equity: 1046416000.00
TCBK balance_sheet (annual, 2022-12-31) — Tangible Book Value: 725304000.00
TCBK income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -986265.00
TCBK income_statement (annual, 2022-12-31) — Tax Provision: 48488000.00
TCBK income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.28
TCBK balance_sheet (annual, 2022-12-31) — Total Assets: 9930986000.00
TCBK balance_sheet (annual, 2022-12-31) — Total Capitalization: 1412061000.00
TCBK balance_sheet (annual, 2022-12-31) — Total Debt: 394649000.00
TCBK balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 1046416000.00
TCBK balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 8884570000.00
TCBK income_statement (annual, 2022-12-31) — Total Unusual Items: -3535000.00
TCBK income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -3535000.00
TCBK income_statement (annual, 2023-12-31) — +Total Revenue: 411130000.00
TCBK balance_sheet (annual, 2023-12-31) — Accounts Payable: 8445000.00
TCBK balance_sheet (annual, 2023-12-31) — Accounts Receivable: 36768000.00
TCBK balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -65154000.00
TCBK income_statement (annual, 2023-12-31) — Amortization: 6118000.00
TCBK cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 6118000.00
TCBK cash_flow (annual, 2023-12-31) — Amortization Of Intangibles: 6118000.00
TCBK income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 6118000.00
TCBK balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 2634000.00
TCBK income_statement (annual, 2023-12-31) — Basic Average Shares: 33261169.00
TCBK income_statement (annual, 2023-12-31) — Basic EPS: 3.53
TCBK cash_flow (annual, 2023-12-31) — Beginning Cash Position: 107230000.00
TCBK balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 65467000.00
TCBK cash_flow (annual, 2023-12-31) — Capital Expenditure: -4886000.00
TCBK balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 28261000.00
TCBK balance_sheet (annual, 2023-12-31) — Capital Stock: 697349000.00
TCBK balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 98701000.00
TCBK balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Federal Funds Sold: 115951000.00
TCBK cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -39901000.00
TCBK balance_sheet (annual, 2023-12-31) — Cash Financial: 81626000.00
TCBK cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -175983000.00
TCBK cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 28567000.00
TCBK cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 138887000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Account Payable: 7278000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -18647000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Payable: 7278000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 7278000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Receivables: -4912000.00
TCBK cash_flow (annual, 2023-12-31) — Change In Working Capital: -16281000.00
TCBK cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -4912000.00
TCBK cash_flow (annual, 2023-12-31) — Changes In Cash: -8529000.00
TCBK balance_sheet (annual, 2023-12-31) — Common Stock: 697349000.00
TCBK cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -39901000.00
TCBK balance_sheet (annual, 2023-12-31) — Common Stock Equity: 1159682000.00
TCBK cash_flow (annual, 2023-12-31) — Common Stock Payments: -9240000.00
TCBK balance_sheet (annual, 2023-12-31) — Construction In Progress: 1018000.00
TCBK balance_sheet (annual, 2023-12-31) — Current Debt: 32582000.00
TCBK balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 32582000.00
TCBK cash_flow (annual, 2023-12-31) — Deferred Income Tax: -2399000.00
TCBK cash_flow (annual, 2023-12-31) — Deferred Tax: -2399000.00
TCBK cash_flow (annual, 2023-12-31) — Depreciation: 12730000.00
TCBK cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 18848000.00
TCBK income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 6118000.00
TCBK cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 18848000.00
TCBK income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 6118000.00
TCBK income_statement (annual, 2023-12-31) — Diluted Average Shares: 33352564.00
TCBK income_statement (annual, 2023-12-31) — Diluted EPS: 3.52
TCBK income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 117390000.00
TCBK cash_flow (annual, 2023-12-31) — End Cash Position: 98701000.00
TCBK cash_flow (annual, 2023-12-31) — Financing Cash Flow: -175983000.00
TCBK cash_flow (annual, 2023-12-31) — Free Cash Flow: 134001000.00
TCBK cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 248000.00
TCBK cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 23000.00
TCBK income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -248000.00
TCBK balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -153169000.00
TCBK income_statement (annual, 2023-12-31) — General And Administrative Expense: 141071000.00
TCBK balance_sheet (annual, 2023-12-31) — Goodwill: 304442000.00
TCBK balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 314994000.00
TCBK balance_sheet (annual, 2023-12-31) — Gross PPE: 162634000.00
TCBK balance_sheet (annual, 2023-12-31) — Held To Maturity Securities: 133494000.00
TCBK cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 45300000.00
TCBK income_statement (annual, 2023-12-31) — Insurance And Claims: 5276000.00
TCBK income_statement (annual, 2023-12-31) — Interest Expense: 81677000.00
TCBK income_statement (annual, 2023-12-31) — Interest Income: 437060000.00
TCBK cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 74399000.00
TCBK balance_sheet (annual, 2023-12-31) — Invested Capital: 1893363000.00
TCBK cash_flow (annual, 2023-12-31) — Investing Cash Flow: 28567000.00
TCBK balance_sheet (annual, 2023-12-31) — Investments And Advances: 2288632000.00
TCBK cash_flow (annual, 2023-12-31) — Issuance Of Debt: 367977000.00
TCBK balance_sheet (annual, 2023-12-31) — Land And Improvements: 26032000.00
TCBK balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 28261000.00
TCBK balance_sheet (annual, 2023-12-31) — Long Term Debt: 733681000.00
TCBK balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 761942000.00
TCBK cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 367977000.00
TCBK cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
TCBK balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 43984000.00
TCBK cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
TCBK cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -9240000.00
TCBK balance_sheet (annual, 2023-12-31) — Net Debt: 634980000.00
TCBK income_statement (annual, 2023-12-31) — Net Income: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 117390000.00
TCBK cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 117390000.00
TCBK income_statement (annual, 2023-12-31) — Net Interest Income: 355383000.00
TCBK cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 385554000.00
TCBK cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 367977000.00
TCBK cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 367977000.00
TCBK cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 224000.00
TCBK balance_sheet (annual, 2023-12-31) — Net PPE: 97480000.00
TCBK cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -4886000.00
TCBK balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 844688000.00
TCBK income_statement (annual, 2023-12-31) — Normalized Income: 116300110.00
TCBK income_statement (annual, 2023-12-31) — Occupancy And Equipment: 21779000.00
TCBK cash_flow (annual, 2023-12-31) — Operating Cash Flow: 138887000.00
TCBK cash_flow (annual, 2023-12-31) — Operating Gains Losses: -1009000.00
TCBK income_statement (annual, 2023-12-31) — Operating Revenue: 411130000.00
TCBK balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 33268102.00
TCBK balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 32582000.00
TCBK balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -153169000.00
TCBK balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 10552000.00
TCBK cash_flow (annual, 2023-12-31) — Other Non Cash Items: -6089000.00
TCBK income_statement (annual, 2023-12-31) — Other Non Interest Expense: 46355000.00
TCBK balance_sheet (annual, 2023-12-31) — Other Properties: 26133000.00
TCBK balance_sheet (annual, 2023-12-31) — Other Receivables: 8250000.00
TCBK balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 2152504000.00
TCBK income_statement (annual, 2023-12-31) — Other Special Charges: 23000.00
TCBK balance_sheet (annual, 2023-12-31) — Payables: 8445000.00
TCBK balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 8445000.00
TCBK balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
TCBK income_statement (annual, 2023-12-31) — Pretax Income: 160905000.00
TCBK cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 156000.00
TCBK income_statement (annual, 2023-12-31) — Professional Expense And Contract Services Expense: 7358000.00
TCBK cash_flow (annual, 2023-12-31) — Purchase Of Investment: -34468000.00
TCBK cash_flow (annual, 2023-12-31) — Purchase Of PPE: -4886000.00
TCBK balance_sheet (annual, 2023-12-31) — Receivables: 45018000.00
TCBK income_statement (annual, 2023-12-31) — Reconciled Depreciation: 18848000.00
TCBK cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
TCBK cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -9240000.00
TCBK income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 0.00
TCBK balance_sheet (annual, 2023-12-31) — Retained Earnings: 615502000.00
TCBK income_statement (annual, 2023-12-31) — Salaries And Wages: 135795000.00
TCBK cash_flow (annual, 2023-12-31) — Sale Of Investment: 420022000.00
TCBK cash_flow (annual, 2023-12-31) — Sale Of PPE: 0.00